A case of basal cell nevus syndrome with a SUFU mutation
DOI:
https://doi.org/10.5070/kqdbtw18Keywords:
Gorlin syndrome, SUFU mutationAbstract
Basal cell nevus syndrome (Gorlin syndrome) is a rare genetic condition characterized by multiple basal cell carcinomas, often arising before age 20. Most cases result from a mutation in the patched 1 gene—part of the sonic hedgehog pathway. Rarely, this condition is related to a suppressor of fused gene mutation, which occurs downstream from Smoothened, and is unresponsive to Smoothened inhibitors including vismodegib and sonidegib. Notably, basal cell nevus syndrome, secondary to a suppressor of fused gene mutation, is associated with a higher incidence of childhood medulloblastoma with implications for the patient and offspring.
A 72-year-old man with pearly papules coalescing into plaques across the nose and cheeks presented. The lesions had appeared as a teenager, and the patient reported his sister had similar lesions. Five biopsies, reviewed by three dermatopathologists, were consistent with basal cell carcinoma. Genetic testing was negative for patched 1 and patched 2 mutations but positive for a heterozygous suppressor of fused mutation. Patients with basal cell nevus syndrome should be treated with surgical excision, counseled on sun protection, screened and monitored for complications, and treated with vismodegib (if associated with patched 1 mutation) or itraconazole (if associated with suppressor of fused mutation).
Downloads
References
1. Huq AJ, Walsh M, Rajagopalan B, et al. Mutations in SUFU and PTCH1 genes may cause different cutaneous cancer predisposition syndromes: Similar, but not the same. Fam Cancer. 2018;17(4):601-606. [PMID: 29356994].
2. Fernández LT, Ocampo-Garza SS, Elizondo-Riojas G, Ocampo-Candiani J. Basal cell nevus syndrome: An update on clinical findings. Int J Dermatol. 2022;61(9):1047-1055. Published online September 8, 2021. [PMID: 34494262].
3. Ogden T, Higgins S, Elbaum D, Wysong A. The relevance of a suppressor of fused (SUFU) mutation in the diagnosis and treatment of Gorlin syndrome. JAAD Case Rep. 2018;4(2):196-199. [PMID: 29892665].
4. Agrawal A, Murari A, Vutukuri S, Singh A. Gorlin-goltz syndrome: Case report of a rare hereditary disorder. Case Rep Dent. 2012;2012:475439. [PMID: 23050170].
5. Colegio O, O’Toole E, Pontén F, Lundeberg J, Asplund A. In: Bolognia J, Schaffer J, Cerroni L, eds. Dermatology. 4th ed. Elsevier Limited; 2018:1870.
6. Barankin B, Lam J. Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome). In: Stern R, Robinson J, eds. UpToDate. UpToDate; 2022. Accessed August 30, 2022.
7. Evans DG, Ladusans EJ, Rimmer S, et al. Complications of the naevoid basal cell carcinoma syndrome: Results of a population-based study. J Med Genet. 1993;30(6):460-464. [PMID: 8326488].
8. Kim CS, Na YC. Basal cell nevus syndrome with excessive basal cell carcinomas. Arch Craniofac Surg.2021;22(2):122-125. [PMID: 33957740].
9. Hasan Ali O, Yurchenko AA, Pavlova O, et al. Genomic profiling of late-onset basal cell carcinomas from two brothers with Nevoid basal cell carcinoma syndrome. J Eur Acad Dermatol Venereol. 2021;35(2):396-402. [PMID: 32564428].
10. Ligtenberg KG, Hu JK, Damsky W, et al. Neoadjuvant anti-programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Rep. 2020;6(7):628-633. [PMID: 32613057].
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Joshua Aron, Mikel Muse, Blair Harris, Madison Reed, Jonathan Crane, Rene Bermudez (Author)

This work is licensed under a Creative Commons Attribution 4.0 International License.